Literature DB >> 1767539

Management of hyperparathyroid patients with grave hypercalcemia.

L E Tisell1, G Hedbäck, S Jansson, G Lindstedt, B F Zachrisson.   

Abstract

During recent years the total number of patients undergoing surgery for hyperparathyroidism has markedly increased, but the annual number of cases with substantial hypercalcemia has remained unchanged. Parathyroid carcinoma and water clear cell hyperplasia cause more severe hypercalcemia than other kinds of hyperparathyroidism. Grave hypercalcemia due to hyperparathyroidism is more common among the elderly, but can occur during pregnancy and also among children. Occasionally, a patient with hyperparathyroidism can also have another cause of the hypercalcemia and does not become normocalcemic until adequately treated for both. The suspicion of grave hypercalcemia should arise due to its clinical features. Determination of serum calcium and intact parathyroid hormone concentrations establishes the diagnosis. The basic treatment of grave hypercalcemia is to rehydrate the patient and to restore the sodium losses. To further lower the serum calcium value we have found bisphosphonates to be very effective. The definitive treatment of grave hypercalcemia due to hyperparathyroidism is surgery. As a last resort, frail patients with grave hyperparathyroidism can undergo surgery under local anesthesia. Repeat operations can improve the prognosis of patients with metastatic parathyroid carcinoma. Selective venous catheterization with blood sampling for determination of intact parathyroid hormone can be helpful in localizing recurrent disease.

Entities:  

Mesh:

Year:  1991        PMID: 1767539     DOI: 10.1007/bf01665307

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  45 in total

1.  Hypercalcemia without hypercalcuria or hypophosphatemia, calcinosis and renal insufficiency; a syndrome following prolonged intake of milk and alkali.

Authors:  C H BURNETT; R R COMMONS
Journal:  N Engl J Med       Date:  1949-05-19       Impact factor: 91.245

2.  Comparison of poly- and monoclonal antibodies as labels in a two-site immunochemiluminometric assay for intact parathyroid hormone.

Authors:  R C Brown; J P Aston; A St John; J S Woodhead
Journal:  J Immunol Methods       Date:  1988-04-22       Impact factor: 2.303

3.  Studies of the mechanism by which phosphate infusion lowers serum calcium concentration.

Authors:  L A Hebert; J Lemann; J R Petersen; E J Lennon
Journal:  J Clin Invest       Date:  1966-12       Impact factor: 14.808

4.  Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.

Authors:  J J Body; A Borkowski; A Cleeren; O L Bijvoet
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

5.  Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis.

Authors:  N H Bell; P H Stern; E Pantzer; T K Sinha; H F DeLuca
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

6.  Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.

Authors:  H I Harinck; O L Bijvoet; A S Plantingh; J J Body; J W Elte; H P Sleeboom; J Wildiers; J P Neijt
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

7.  Lethal hyperparathyroid crisis: hazards of phosphate administration.

Authors:  A M Vernava; L W O'Neal; V Palermo
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

8.  Lithium's effect of parathyroid hormone.

Authors:  B M Davis; A Pfefferbaum; S Krutzik; K L Davis
Journal:  Am J Psychiatry       Date:  1981-04       Impact factor: 18.112

9.  Improvement of muscle strength after treatment for hyperparathyroidism.

Authors:  I Hedman; G Grimby; L E Tisell
Journal:  Acta Chir Scand       Date:  1984

10.  Hypercalcaemia--a hospital survey.

Authors:  R A Fisken; D A Heath; A M Bold
Journal:  Q J Med       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.